After
we turn 30, we all lose muscle and strength at the rate of 1% a year. MYOS
Corporation intends to reverse that.
MYOS
Corporation focuses on the formulation, acquisition, and distribution of
nutritional, nutraceutical, physical performance enhancement, and wellness
products that focus solely on maintaining or improving the health and
performance of muscle tissue. Currently the company has on the market MYO-T12,
a dietary supplement product for optimizing biological activity, which is
marketed at retail stores like GNC as MYO-X.
Myostatin
is a structurally related regulatory protein produced in our bodies that
inhibits muscle differentiation and growth which our bodies needed mainly at
the time of embryonic development. MYOS Corp.’s products focus on inhibiting
the activity of myostatin.
While
the company has products appreciated by those seeking to build muscle mass, the
company aims to treat sarcopenia. Sarcopenia is the progressive loss of muscle
that comes with aging. If a person has problems with at least three of the
following conditions, they probably have this degenerative muscle disease:
problems in lifting or carrying three pounds, need assistance walking, have
trouble rising from a chair, have difficulty climbing a set of stairs, or
tendency to fall in the past six months.
The
population of people in the United States of age 65 increased from 35 million
in the year 2000 to about 40 million people in 2010, and that is expected to
grow to 72.1 million people. Estimates suggest 45% of that older population
suffer from sarcopenia, which amounts to 18 million people, and that number is
expected to rise. Of the 1.5 million older people that end up institutionalized
into nursing homes and long-term care facilities, about one third were admitted
because of their inability to perform the basic activities of daily living.
About 1.5% of total healthcare expenditures, or $18.5 billion, are directly
attributable to treating sarcopenia. The U.S. spends $26 billion additionally
on people over the age of 65 that lose the ability to perform daily activities.
With
no drugs on the market approved by the FDA for treatment of Sarcopenia, a
resistance training program and supplements from MYOS under the guidance of a
geriatrician can play a major role in treating those that suffer from this
condition. MYOS Corp. has an aggressive business and marketing strategy which
opens the door to opportunity.
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see
disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
